Clinical Trials Browser

Refractory or Recurrent Solid Tumor × spartalizumab × Clear all

NCT05210413 2026-01-15

SPARTO

Phase 1/2 Active not recruiting

Other solid neoplasm

Refractory or Recurrent Solid Tumor